hepatomiR cACLD Study

Last updated: May 24, 2024
Sponsor: Karl Landsteiner University of Health Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

Liver Disorders

Diabetes And Hypertension

Primary Biliary Cholangitis

Treatment

hepatomiR

Clinical Study ID

NCT06432582
UKStP_hepatomiR_cACLD
  • Ages > 18
  • All Genders

Study Summary

This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Chronic liver disease (more than 6 months)

  • LSM ≥ 10 kPa

  • Outpatient at the Clinical Department of Internal Medicine II, University HospitalSt. Pölten

  • Signed patient consent form

Exclusion

Exclusion Criteria:

  • Age older than 18 years

  • Pregnancy

  • Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) withportal invasion and/or extrahepatic spread

Study Design

Total Participants: 156
Treatment Group(s): 1
Primary Treatment: hepatomiR
Phase:
Study Start date:
May 15, 2024
Estimated Completion Date:
June 30, 2026

Connect with a study center

  • University Hospital St. Pölten

    St. Pölten, Lower Austria 3100
    Austria

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.